{
    "hands_on_practices": [
        {
            "introduction": "Clinical diagnostic criteria, such as the Boston Criteria for cerebral amyloid angiopathy, provide a standardized framework for diagnosis, but they are not infallible. To move from a 'positive' or 'negative' classification to a more nuanced and quantitative estimate of disease probability, clinicians can employ Bayes' theorem. This exercise provides hands-on practice in using this fundamental statistical tool to calculate the posterior probability of CAA, helping to translate a test result into a more precise measure of diagnostic certainty. ",
            "id": "4465326",
            "problem": "A clinician evaluates an older adult with lobar intracerebral hemorrhage (ICH) for suspected cerebral amyloid angiopathy (CAA). The Boston Criteria version $2.0$ classification is treated as a binary diagnostic test where a “positive” classification indicates that the criteria are met for probable CAA. Assume the following well-tested diagnostic performance characteristics for this classification in this clinical context: sensitivity $0.85$, specificity $0.80$. The clinician’s pretest probability for CAA in this lobar ICH presentation is $0.50$. Using the definition of sensitivity as $\\mathbb{P}(\\text{positive} \\mid \\text{CAA})$, specificity as $\\mathbb{P}(\\text{negative} \\mid \\neg \\text{CAA})$, and Bayes’ theorem for conditional probabilities, compute the posterior probability $\\mathbb{P}(\\text{CAA} \\mid \\text{positive})$. Express your answer as a decimal rounded to four significant figures. Do not use a percent sign.",
            "solution": "The problem is subjected to validation.\n**Step 1: Extract Givens**\n- The context is the diagnosis of cerebral amyloid angiopathy (CAA) in an older adult with lobar intracerebral hemorrhage (ICH).\n- The diagnostic test is the Boston Criteria version $2.0$.\n- Sensitivity of the test: $\\text{sens} = \\mathbb{P}(\\text{positive} \\mid \\text{CAA}) = 0.85$.\n- Specificity of the test: $\\text{spec} = \\mathbb{P}(\\text{negative} \\mid \\neg \\text{CAA}) = 0.80$.\n- Pretest probability of CAA: $\\mathbb{P}(\\text{CAA}) = 0.50$.\n- The objective is to compute the posterior probability $\\mathbb{P}(\\text{CAA} \\mid \\text{positive})$.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded:** The problem is grounded in standard probability theory (Bayes' theorem) and its application in medical diagnostics, which is a well-established scientific practice. The clinical context is realistic, using a known diagnostic criterion (Boston Criteria for CAA).\n- **Well-Posed:** The problem provides all necessary information—pretest probability, sensitivity, and specificity—to calculate the required posterior probability. A unique solution exists and can be determined.\n- **Objective:** The problem statement is quantitative and free of subjective or ambiguous language.\n\n**Step 3: Verdict and Action**\n- The problem is deemed valid. A solution will be derived.\n\nTo solve this problem, we will use Bayes' theorem for conditional probability. Let $C$ denote the event that the patient has cerebral amyloid angiopathy, and let $\\neg C$ denote the event that the patient does not have CAA. Let $+$ denote the event of a positive test result (i.e., the Boston Criteria for probable CAA are met). We are asked to find the posterior probability $\\mathbb{P}(C \\mid +)$.\n\nFrom the problem statement, we are given the following probabilities:\nThe pretest probability, or prevalence, of CAA is $\\mathbb{P}(C) = 0.50$.\nThe sensitivity of the test is the probability of a positive test given the presence of the disease: $\\mathbb{P}(+ \\mid C) = 0.85$.\nThe specificity of the test is the probability of a negative test given the absence of the disease: $\\mathbb{P}(\\text{negative} \\mid \\neg C) = 0.80$.\n\nFirst, we must determine the probabilities of the complementary events. The probability of not having CAA is:\n$$ \\mathbb{P}(\\neg C) = 1 - \\mathbb{P}(C) = 1 - 0.50 = 0.50 $$\nThe probability of a positive test given the absence of the disease (the false positive rate) is $1$ minus the specificity:\n$$ \\mathbb{P}(+ \\mid \\neg C) = 1 - \\mathbb{P}(\\text{negative} \\mid \\neg C) = 1 - 0.80 = 0.20 $$\n\nBayes' theorem is stated as:\n$$ \\mathbb{P}(C \\mid +) = \\frac{\\mathbb{P}(+ \\mid C) \\mathbb{P}(C)}{\\mathbb{P}(+)} $$\nThe denominator, $\\mathbb{P}(+)$, is the total probability of a positive test result. It can be calculated using the law of total probability:\n$$ \\mathbb{P}(+) = \\mathbb{P}(+ \\mid C)\\mathbb{P}(C) + \\mathbb{P}(+ \\mid \\neg C)\\mathbb{P}(\\neg C) $$\n\nNow, we can substitute the known values into these formulas.\nFirst, we calculate the total probability of a positive test, $\\mathbb{P}(+)$:\n$$ \\mathbb{P}(+) = (0.85)(0.50) + (0.20)(0.50) $$\n$$ \\mathbb{P}(+) = 0.425 + 0.100 $$\n$$ \\mathbb{P}(+) = 0.525 $$\n\nNext, we use this value in Bayes' theorem to find the posterior probability $\\mathbb{P}(C \\mid +)$. The numerator is the probability of having the disease and testing positive:\n$$ \\mathbb{P}(C \\cap +) = \\mathbb{P}(+ \\mid C)\\mathbb{P}(C) = (0.85)(0.50) = 0.425 $$\n\nTherefore, the posterior probability is:\n$$ \\mathbb{P}(C \\mid +) = \\frac{\\mathbb{P}(+ \\mid C)\\mathbb{P}(C)}{\\mathbb{P}(+)} = \\frac{0.425}{0.525} $$\n$$ \\mathbb{P}(C \\mid +) \\approx 0.8095238095... $$\n\nThe problem requires the answer to be expressed as a decimal rounded to four significant figures.\n$$ \\mathbb{P}(C \\mid +) \\approx 0.8095 $$\nThis value, also known as the positive predictive value in this context, is the probability that the patient has CAA, given that their test result was positive.",
            "answer": "$$ \\boxed{0.8095} $$"
        },
        {
            "introduction": "Pathological processes in the brain rarely exist in isolation; a common challenge in neurovascular medicine is the presence of mixed small vessel disease, where cerebral amyloid angiopathy and hypertensive arteriopathy coexist. Interpreting imaging that shows both lobar markers of CAA and deep markers of hypertensive disease requires careful clinical reasoning and a deep understanding of the underlying pathophysiology. This case-based exercise challenges you to apply modern diagnostic frameworks to a patient with a mixed hemorrhagic pattern, forcing a consideration beyond a simple 'pure CAA' diagnosis. ",
            "id": "4465380",
            "problem": "A patient aged $76$ years with a history of $2$ spontaneous nontraumatic occipital lobar intracerebral hemorrhages presents for evaluation. Blood pressure is currently well controlled without antihypertensive medications, and there is no history of antithrombotic exposure at the time of either hemorrhage. Magnetic resonance imaging with susceptibility-weighted imaging demonstrates a single thalamic microbleed and multiple strictly lobar microbleeds. There is no evidence of cortical superficial siderosis on gradient-echo sequences. Based on the core pathoanatomy that cerebral amyloid angiopathy (CAA) predominantly involves leptomeningeal and cortical penetrating arterioles within the lobar territories, whereas hypertensive arteriopathy predominantly affects deep perforator arterioles supplying the basal ganglia, thalamus, brainstem, and deep cerebellar nuclei, reason whether the presence of a single deep (thalamic) microbleed should prompt reconsideration of a diagnosis of pure CAA under modern diagnostic frameworks, and propose the most appropriate differential interpretation of this imaging pattern.\n\nWhich of the following is the most appropriate interpretation?\n\nA. The single thalamic microbleed is nonspecific and does not affect classification; the patient still meets probable CAA, and the pattern is best explained by pure cerebral amyloid angiopathy.\n\nB. The presence of a deep thalamic microbleed reduces the likelihood of pure cerebral amyloid angiopathy under validated criteria; the overall pattern is most consistent with mixed small vessel disease due to coexisting cerebral amyloid angiopathy and hypertensive arteriopathy.\n\nC. The deep thalamic microbleed indicates cerebral amyloid angiopathy-related inflammation, and high-dose glucocorticoids are indicated regardless of other imaging.\n\nD. Any deep microbleed rules out cerebral amyloid angiopathy entirely; recurrent lobar hemorrhages must be due to an underlying arteriovenous malformation that was missed on prior imaging.\n\nE. The deep microbleed localizes the pathophysiology to penetrating artery disease; therefore, cerebral amyloid angiopathy is excluded and future anticoagulation can be considered low risk.",
            "solution": "## PROBLEM VALIDATION\n\n### Step 1: Extract Givens\nThe problem provides the following clinical and imaging data for a patient:\n-   **Age**: $76$ years\n-   **Clinical History**: History of $2$ spontaneous nontraumatic occipital lobar intracerebral hemorrhages (ICHs).\n-   **Medication History**: No history of antithrombotic exposure at the time of either hemorrhage.\n-   **Vital Signs**: Blood pressure is currently well controlled without antihypertensive medications.\n-   **Magnetic Resonance Imaging (MRI) Findings**:\n    -   Susceptibility-weighted imaging (SWI) demonstrates a single thalamic microbleed.\n    -   SWI also demonstrates multiple strictly lobar microbleeds.\n    -   Gradient-echo (GRE) sequences show no evidence of cortical superficial siderosis (cSS).\n-   **Pathophysiological Premise**: Cerebral amyloid angiopathy (CAA) predominantly involves leptomeningeal and cortical penetrating arterioles in lobar territories. Hypertensive arteriopathy predominantly affects deep perforator arterioles supplying the basal ganglia, thalamus, brainstem, and deep cerebellar nuclei.\n-   **Question**: Reason whether the single deep (thalamic) microbleed should prompt reconsideration of a diagnosis of pure CAA, and propose the most appropriate differential interpretation of the imaging pattern.\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientific Grounding**: The problem is scientifically grounded. The patient's presentation (elderly, recurrent spontaneous lobar ICHs) and imaging findings (lobar microbleeds) are classic for cerebral amyloid angiopathy. The provided pathophysiological distinction between CAA (lobar) and hypertensive arteriopathy (deep) is accurate and forms the basis of modern diagnostic criteria for cerebral small vessel diseases (SVD). The central question addresses a common and important clinical dilemma: the interpretation of mixed (lobar and deep) hemorrhagic patterns. This is a topic of active research and clinical importance, governed by established criteria like the Boston Criteria for CAA.\n2.  **Well-Posed**: The problem is well-posed. It provides sufficient clinical and imaging data to apply standardized diagnostic criteria and to formulate a reasoned differential interpretation. The question asks for the \"most appropriate interpretation,\" which is a standard task in clinical reasoning, leading to a preferred diagnosis based on the evidence.\n3.  **Objective**: The problem is stated in objective, clinical language, free of bias or subjective claims. The data points are factual findings from a patient history and imaging report.\n\nThe problem is a valid clinical reasoning exercise in neurology, requiring the application of established knowledge and diagnostic criteria. It is not unsound, incomplete, ambiguous, or otherwise flawed.\n\n### Step 3: Verdict and Action\nThe problem statement is **valid**. The solution will proceed by analyzing the findings in the context of the Boston Criteria for CAA and the known pathophysiology of cerebral small vessel diseases.\n\n## SOLUTION\n\nThe patient is a $76$-year-old with a history of two spontaneous lobar intracerebral hemorrhages (ICHs). MRI reveals multiple strictly lobar microbleeds and a single thalamic microbleed, with no cortical superficial siderosis. The problem requires an interpretation of this specific pattern of findings.\n\nThe leading diagnostic framework for cerebral amyloid angiopathy (CAA) is the Boston Criteria, most recently updated to version $2.0$. These criteria integrate clinical, imaging, and pathological findings to establish the likelihood of CAA.\n\nAccording to the Boston Criteria $2.0$, a diagnosis of \"probable CAA\" can be made in a living person (in vivo) without a brain biopsy. The criteria for probable CAA are:\n1.  Age $\\ge 50$ years.\n2.  Spontaneous presentation with ICH, convexity subarachnoid hemorrhage (cSAH), transient focal neurological episodes (TFNEs), or cognitive impairment.\n3.  MRI demonstrating at least two of the following strictly lobar hemorrhagic lesion types: ICHs, microbleeds (MBs), or cortical superficial siderosis (cSS)/cSAH.\n4.  No other cause for hemorrhage.\n\nLet's apply these criteria to the patient:\n1.  Age is $76$, which is $\\ge 50$.\n2.  The patient presents with a history of two spontaneous lobar ICHs.\n3.  The MRI shows multiple lobar microbleeds and a history of two lobar ICHs. This fulfills the requirement for $\\ge 2$ strictly lobar hemorrhagic lesion types.\n4.  No other cause is mentioned, and the history is of spontaneous, nontraumatic hemorrhages.\n\nBased on the lobar findings alone, the patient would meet the criteria for \"probable CAA\". However, the critical feature is the single thalamic microbleed. The thalamus is a deep brain structure, and bleeds in this location are characteristically associated with hypertensive arteriopathy, not CAA.\n\nThe Boston Criteria $2.0$ and subsequent expert consensus explicitly address the issue of mixed lobar and deep findings. While the original criteria for \"probable CAA\" required the absence of any deep hemorrhages to ensure high specificity for CAA pathology, it is now widely recognized that CAA and hypertensive arteriopathy frequently coexist, a condition known as mixed small vessel disease. Neuropathological studies have confirmed that patients with pathologically-proven CAA can have a small number of deep microbleeds.\n\nTherefore, the presence of a deep microbleed does not entirely exclude the diagnosis of CAA. Instead, it modifies the interpretation. The presence of a single thalamic microbleed serves as a marker for co-existing hypertensive arteriopathy. The overwhelming burden of disease is lobar ($2$ ICHs, multiple MBs), which strongly supports CAA as the dominant pathology and the cause of the major clinical events (the lobar ICHs). The single deep microbleed points to a second, concurrent pathological process. Thus, the most accurate interpretation is not *pure* CAA, but a *mixed* pathology of CAA and hypertensive arteriopathy. The fact that the patient's blood pressure is currently well-controlled without medication does not rule out a past or cumulative effect of hypertension, or age-related deep arteriopathy, which is pathologically identical.\n\n### Option-by-Option Analysis\n\n**A. The single thalamic microbleed is nonspecific and does not affect classification; the patient still meets probable CAA, and the pattern is best explained by pure cerebral amyloid angiopathy.**\nThis statement is **Incorrect**. A thalamic microbleed is a highly specific marker for deep perforator arteriopathy, the substrate of hypertensive vasculopathy. It is not \"nonspecific\". Its presence fundamentally affects the interpretation by introducing a second pathology. Claiming the pattern is best explained by \"pure\" CAA is incorrect, as this dismisses a key finding that points to a mixed etiology.\n\n**B. The presence of a deep thalamic microbleed reduces the likelihood of pure cerebral amyloid angiopathy under validated criteria; the overall pattern is most consistent with mixed small vessel disease due to coexisting cerebral amyloid angiopathy and hypertensive arteriopathy.**\nThis statement is **Correct**. The deep microbleed makes a diagnosis of *pure* CAA less likely. The combination of extensive lobar disease (multiple lobar ICHs and microbleeds) with a marker of deep arteriopathy (thalamic microbleed) is the classic picture of mixed small vessel disease, where both CAA and hypertensive arteriopathy are present. This is the most accurate and clinically relevant interpretation.\n\n**C. The deep thalamic microbleed indicates cerebral amyloid angiopathy-related inflammation, and high-dose glucocorticoids are indicated regardless of other imaging.**\nThis statement is **Incorrect**. Cerebral amyloid angiopathy-related inflammation (CAA-ri) is a distinct clinical-radiological syndrome characterized by subacute cognitive decline and seizures, with MRI findings of extensive, asymmetric, patchy, or confluent T2-hyperintense white matter lesions that can be vasogenic edema. A single, isolated deep microbleed is not a diagnostic feature of CAA-ri. Initiating high-dose glucocorticoids based on this single finding would be inappropriate and potentially harmful.\n\n**D. Any deep microbleed rules out cerebral amyloid angiopathy entirely; recurrent lobar hemorrhages must be due to an underlying arteriovenous malformation that was missed on prior imaging.**\nThis statement is **Incorrect**. This is an overly rigid interpretation that is inconsistent with modern understanding and the Boston Criteria 2.0. As discussed, mixed pathologies are common. A single deep microbleed does not rule out CAA, especially in the face of overwhelming evidence for it (recurrent lobar ICHs). Attributing the lobar hemorrhages to a hypothetically missed arteriovenous malformation (AVM) is speculative and dismisses the most likely diagnosis based on the complete constellation of findings in a patient of this age.\n\n**E. The deep microbleed localizes the pathophysiology to penetrating artery disease; therefore, cerebral amyloid angiopathy is excluded and future anticoagulation can be considered low risk.**\nThis statement is **Incorrect**. While the first clause is partially correct (the deep microbleed is related to deep penetrating artery disease), the conclusions are dangerously flawed. It is a grave error to exclude CAA when there is massive evidence for it ($2$ lobar ICHs, multiple lobar microbleeds). The presence of CAA signifies a very high risk of future hemorrhage, and this risk is significantly amplified by anticoagulation. To ignore the CAA component and declare anticoagulation \"low risk\" would represent a serious clinical mistake with potentially catastrophic consequences for the patient.",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "One of the most challenging decisions in managing patients with CAA is balancing the risk of ischemic stroke against the risk of catastrophic intracerebral hemorrhage, particularly when considering anticoagulation. Clinical judgment alone can be difficult when weighing such disparate outcomes. This practice introduces a quantitative decision-analysis framework using quality-adjusted life years (QALYs) to structure this complex trade-off, allowing you to derive an explicit threshold for when anticoagulation might offer a net benefit. ",
            "id": "4465385",
            "problem": "A patient with atrial fibrillation and a history of lobar intracerebral hemorrhage due to cerebral amyloid angiopathy (CAA) is being considered for oral anticoagulation. The patient’s Congestive heart failure, Hypertension, Age, Diabetes, prior Stroke/transient ischemic attack, Vascular disease, Age, Sex category (CHA2DS2-VASc) score is $4$, which is associated with an annual ischemic stroke risk of $0.04$ in the absence of anticoagulation. Based on cohort data in cerebral amyloid angiopathy, the annual recurrence risk of lobar intracerebral hemorrhage (ICH) without anticoagulation is estimated at $0.10$. Assume a one-year decision horizon.\n\nAssume that anticoagulation confers a multiplicative relative risk reduction $r$ for ischemic stroke (so that the treated ischemic stroke risk is $0.04 \\times (1 - r)$) and multiplies the one-year lobar ICH risk by a factor $k \\geq 1$ (so that the treated ICH risk is $k \\times 0.10$). Use a first-order approximation in which the probability of experiencing both events within one year is negligible.\n\nLet the quality-adjusted life year (QALY) loss per ischemic stroke be $0.40$, the QALY loss per lobar ICH be $0.80$, and the disutility of taking anticoagulation for one year (including bleeding monitoring and treatment burden) be $0.01$ QALY. Use expected-value reasoning to compare strategies.\n\nDerive, in closed form, the minimal relative risk reduction $r$ required as a function of $k$ such that anticoagulation yields a nonnegative expected one-year net QALY benefit compared with no anticoagulation. Express your final result as a single simplified analytic expression in terms of $k$. Do not provide an inequality. Do not include units in your final expression.",
            "solution": "The problem asks for the minimal relative risk reduction, $r$, required for the strategy of anticoagulation (AC) to be at least as beneficial as the strategy of no anticoagulation (no AC). This can be determined by finding the value of $r$ for which the expected quality-adjusted life years (QALYs) of the two strategies are equal. We will use an expected-value framework over a one-year time horizon.\n\nLet us define the parameters provided in the problem:\n- The annual risk of ischemic stroke (IS) without AC, $P_{\\text{IS, noAC}} = 0.04$.\n- The annual risk of lobar intracerebral hemorrhage (ICH) without AC, $P_{\\text{ICH, noAC}} = 0.10$.\n- The QALY loss associated with an IS, $\\Delta Q_{\\text{IS}} = 0.40$.\n- The QALY loss associated with an ICH, $\\Delta Q_{\\text{ICH}} = 0.80$.\n- The disutility (QALY loss) of taking AC for one year, $\\Delta Q_{\\text{AC}} = 0.01$.\n- The relative risk reduction for IS with AC is denoted by $r$. The risk of IS with AC is $P_{\\text{IS, AC}} = P_{\\text{IS, noAC}} \\times (1 - r) = 0.04(1 - r)$.\n- The multiplicative factor for ICH risk with AC is denoted by $k$, where $k \\ge 1$. The risk of ICH with AC is $P_{\\text{ICH, AC}} = k \\times P_{\\text{ICH, noAC}} = 0.10k$.\n\nLet $Q_0$ represent the baseline QALYs for a patient who experiences neither an IS nor an ICH over the year. The expected QALY for each strategy is calculated by subtracting the expected QALY losses from this baseline. The problem states to use a first-order approximation where the probability of both an IS and an ICH occurring in the same year is negligible. This allows us to sum the expected losses from each event independently.\n\nFirst, we calculate the expected QALYs for the \"no anticoagulation\" strategy, $E[Q_{\\text{noAC}}]$.\nThe total expected QALY loss is the sum of the expected losses from IS and ICH.\n$$E[\\text{Loss}_{\\text{noAC}}] = (P_{\\text{IS, noAC}} \\times \\Delta Q_{\\text{IS}}) + (P_{\\text{ICH, noAC}} \\times \\Delta Q_{\\text{ICH}})$$\nSubstituting the given values:\n$$E[\\text{Loss}_{\\text{noAC}}] = (0.04 \\times 0.40) + (0.10 \\times 0.80) = 0.016 + 0.080 = 0.096$$\nThe expected QALY for the \"no anticoagulation\" strategy is:\n$$E[Q_{\\text{noAC}}] = Q_0 - E[\\text{Loss}_{\\text{noAC}}] = Q_0 - 0.096$$\n\nNext, we calculate the expected QALYs for the \"anticoagulation\" strategy, $E[Q_{\\text{AC}}]$.\nThis calculation includes the QALY losses from the modified risks of IS and ICH, as well as the inherent disutility of the treatment itself.\nThe expected QALY loss from clinical events is:\n$$E[\\text{Loss}_{\\text{events, AC}}] = (P_{\\text{IS, AC}} \\times \\Delta Q_{\\text{IS}}) + (P_{\\text{ICH, AC}} \\times \\Delta Q_{\\text{ICH}})$$\nSubstituting the expressions for the risks with AC:\n$$E[\\text{Loss}_{\\text{events, AC}}] = (0.04(1 - r) \\times 0.40) + (0.10k \\times 0.80)$$\n$$E[\\text{Loss}_{\\text{events, AC}}] = 0.016(1 - r) + 0.08k$$\nThe total expected QALY for the \"anticoagulation\" strategy is the baseline QALY minus the loss from events and the disutility of treatment:\n$$E[Q_{\\text{AC}}] = Q_0 - \\Delta Q_{\\text{AC}} - E[\\text{Loss}_{\\text{events, AC}}]$$\n$$E[Q_{\\text{AC}}] = Q_0 - 0.01 - (0.016(1 - r) + 0.08k)$$\n$$E[Q_{\\text{AC}}] = Q_0 - 0.01 - 0.016 + 0.016r - 0.08k$$\n$$E[Q_{\\text{AC}}] = Q_0 - 0.026 + 0.016r - 0.08k$$\n\nTo find the minimal relative risk reduction $r$ that justifies anticoagulation, we set the expected QALY of anticoagulation equal to the expected QALY of no anticoagulation. This is the point where the net QALY benefit is zero.\n$$E[Q_{\\text{AC}}] = E[Q_{\\text{noAC}}]$$\n$$Q_0 - 0.026 + 0.016r - 0.08k = Q_0 - 0.096$$\nThe baseline QALY, $Q_0$, cancels out from both sides:\n$$-0.026 + 0.016r - 0.08k = -0.096$$\nNow, we solve for $r$ in terms of $k$:\n$$0.016r = 0.08k - 0.096 + 0.026$$\n$$0.016r = 0.08k - 0.07$$\n$$r = \\frac{0.08k - 0.07}{0.016}$$\nTo simplify this expression, we can multiply the numerator and the denominator by $1000$:\n$$r = \\frac{80k - 70}{16}$$\nDividing the numerator and denominator by their greatest common divisor, which is $2$:\n$$r = \\frac{40k - 35}{8}$$\nThis can also be expressed by separating the terms:\n$$r = \\frac{40k}{8} - \\frac{35}{8}$$\n$$r = 5k - \\frac{35}{8}$$\nThis expression represents the minimal relative risk reduction $r$ required as a function of the ICH risk multiplier $k$ for the net QALY benefit of anticoagulation to be nonnegative.",
            "answer": "$$\\boxed{5k - \\frac{35}{8}}$$"
        }
    ]
}